Arcturus Therapeutics Stocks List Ranked for 2024

	Symbol	Grade	Name	% Change
	TAK	F	Takeda Pharmaceutical Company Limited	0.19
	CVAC	F	CureVac N.V.	-0.40

Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic

Symbol	Grade	Name	Weight
PPH	B	Market Vectors Pharmaceutical ETF	4.23
GERM	D	ETFMG Treatments Testing and Advancements ETF	2.32
FLCO	C	Franklin Liberty Investment Grade Corporate ETF	1.02
BBC	D	Virtus LifeSci Biotech Clinical Trials ETF	0.4
WDNA	D	WisdomTree BioRevolution Fund	0.35

Compare ETFs

Compare BBC to WDNA Compare GERM to BBC Compare GERM to WDNA

Date	Stock	Title
Apr 22	TAK	Pharmas form joint venture to jumpstart Japanese drug research
Apr 22	TAK	Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Apr 19	TAK	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
Apr 18	TAK	U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Apr 18	CVAC	CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Arcturus Therapeutics: Arcturus Therapeutics is an American biotech company focused on the discovery, development and commercialization of therapeutics for rare diseases with focus on RNA. Arcturus has developed a novel, potent and safe RNA therapeutics platform called LUNAR, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, gene editing, DNA, antisense, and microRNA oligotherapeutics.
The company's pipeline includes RNA therapeutics towards rare diseases such as ornithine transcarbamylase deficiency (OTCD), and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19, currently co-developed with Singaporean scientists at Duke–NUS Medical School.